FDA — authorised 1 August 1977
- Application: NDA018012
- Marketing authorisation holder: SPECGX LLC
- Local brand name: PAMELOR
- Indication: SOLUTION — ORAL
- Status: approved
🇺🇸 Switch to nortriptyline in United States
FDA authorised Switch to nortriptyline on 1 August 1977
Marketing authorisations
FDA — authorised 1 August 1977
- Application: NDA018013
- Marketing authorisation holder: SPECGX LLC
- Local brand name: PAMELOR
- Indication: CAPSULE — ORAL
- Status: approved
Other Psychiatry / Mental Health approved in United States
Frequently asked questions
Is Switch to nortriptyline approved in United States?
Yes. FDA authorised it on 1 August 1977; FDA authorised it on 1 August 1977.
Who is the marketing authorisation holder for Switch to nortriptyline in United States?
SPECGX LLC holds the US marketing authorisation.